Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Alnylam Pharmaceuticals	Royalty Pharma	CureVac	Catalent	Ono Pharmaceutical
Symbol	NASDAQ:ALNY	NASDAQ:RPRX	NASDAQ:CVAC	NYSE:CTLT	OTCMKTS:OPHLF
Price Information
Current Price	$138.31	$42.12	$102.61	$109.91	$25.05
52 Week Range	Hold	Hold	Hold	Buy	N/A
MarketRank™
Overall Score	1.8	1.7	0.7	1.7	1.1
Analysis Score	3.2	2.2	1.1	2.4	0.0
Community Score	3.3	2.7	2.2	2.4	2.2
Dividend Score	0.0	1.7	0.0	0.0	0.0
Ownership Score	1.7	0.8	0.0	1.7	0.0
Earnings & Valuation Score	0.6	1.3	0.0	1.9	3.1
Analyst Ratings
Consensus Recommendation	Hold	Hold	Hold	Buy	N/A
Consensus Price Target	$163.42	$51.88	$58.33	$125.13	N/A
% Upside from Price Target	18.16% upside	23.16% upside	-43.15% downside	13.84% upside	N/A
Trade Information
Market Cap	$16.23 billion	$25.57 billion	$19.18 billion	$18.71 billion	$12.88 billion
Beta	1.47	N/A	N/A	1.5	1.06
Average Volume	681,742	3,106,983	833,295	1,068,531	500
Sales & Book Value
Annual Revenue	$219.75 million	N/A	N/A	$3.09 billion	$2.69 billion
Price / Sales	73.84	N/A	N/A	6.05	4.79
Cashflow	N/A	N/A	N/A	$3.57 per share	$1.14 per share
Price / Cash	N/A	N/A	N/A	30.82	21.92
Book Value	$12.90 per share	N/A	N/A	$18.71 per share	$10.16 per share
Price / Book	10.72	N/A	N/A	5.87	2.47
Profitability
Net Income	$-886,120,000.00	N/A	N/A	$173 million	$549.28 million
EPS	($8.11)	N/A	N/A	$1.88	$1.09
Trailing P/E Ratio	N/A	0.00	0.00	70.01	22.77
Forward P/E Ratio	N/A	15.66	N/A	39.68	15.37
P/E Growth	N/A	1.94	N/A	2.68	N/A
Net Margins	-222.19%	N/A	N/A	9.25%	22.14%
Return on Equity (ROE)	-65.96%	N/A	N/A	14.20%	11.29%
Return on Assets (ROA)	-31.38%	N/A	N/A	4.83%	9.71%
Dividend
Annual Payout	N/A	$0.68	N/A	N/A	N/A
Dividend Yield	N/A	1.61%	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	1 Years	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.59%	N/A	0.97%	N/A
Current Ratio	5.32%	10.31%	N/A	2.56%	2.78%
Quick Ratio	5.18%	10.31%	N/A	2.14%	2.33%
Ownership Information
Institutional Ownership Percentage	92.35%	40.85%	4.32%	97.84%	N/A
Insider Ownership Percentage	3.50%	2.50%	N/A	1.00%	N/A
Miscellaneous
Employees	1,453	N/A	500	14,000	3,560
Shares Outstanding	117.32 million	607.11 million	186.91 million	170.23 million	514.12 million
Next Earnings Date	5/5/2021 (Estimated)	5/19/2021 (Estimated)	N/A	5/4/2021 (Estimated)	5/11/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) Sees Significant Increase in Short Interest americanbankingnews.com - April 2 at 1:08 AM
	Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients msn.com - March 23 at 12:35 PM
	Here's what to expect from Ono Pharmaceutical's earnings markets.businessinsider.com - January 31 at 5:58 PM
	News for Ono Pharmaceutical markets.businessinsider.com - December 26 at 8:08 PM
	Fate Therapeutics Jumped On Supportive Trial Data seekingalpha.com - December 18 at 8:10 AM
	Gilead's Cancer Follies seekingalpha.com - October 2 at 7:58 AM
	Ono Pharmaceutical Co., Ltd. (OPHLF) ca.finance.yahoo.com - August 16 at 9:00 AM
	Ono Pharmaceutical Co Ltd (Japan) (OPHLF) www.nasdaq.com - August 2 at 9:35 PM
	Ono Pharmaceutical Co Ltd (Japan) (OPHLF) Short Interest www.nasdaq.com - September 28 at 2:49 AM
	Japanese Nobel laureate Tasuku Honjo to sue Ono Pharmaceutical over cancer drug patent royalties www.japantimes.co.jp - July 28 at 11:14 AM
	Ono Pharmaceutical to make Nobel laureate Tasuku Honjo new offer in bid to settle fee spat over Opdivo www.japantimes.co.jp - July 27 at 10:35 AM
	Fate Therapeutics: Updates To Thesis, Gaining Momentum In The Clinic seekingalpha.com - July 18 at 12:10 PM
	Rafael Pharmaceuticals enters out-licensing agreement with Ono Pharma njbiz.com - June 27 at 11:24 AM
	Rafael Pharmaceuticals, Ono Pharmaceutical to accelerate clinical development of cancer drug candidate CPI-613 www.pharmaceutical-business-review.com - June 26 at 11:37 AM
	Global Opdivo (Nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Market Review & Forecast 2017-2026 - ResearchAndMarkets.com us.acrofan.com - June 24 at 5:33 PM
	Cancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy alliance www.cancerresearchuk.org - March 27 at 12:46 PM
	Vect-Horus enters into Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd. www.marketwatch.com - March 26 at 12:21 PM
	Ono Pharmaceutical and twoXAR Announce Drug Discovery Research Collaboration www.businesswire.com - March 18 at 11:17 AM

Date	Company	Brokerage	Action
3/1/2021	Alnylam Pharmaceuticals	Guggenheim	Reiterated Rating
2/14/2021	Alnylam Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
2/12/2021	Alnylam Pharmaceuticals	Needham & Company LLC	Boost Price Target
2/12/2021	Alnylam Pharmaceuticals	Morgan Stanley	Boost Price Target
2/12/2021	Alnylam Pharmaceuticals	Citigroup	Downgrade
2/12/2021	Alnylam Pharmaceuticals	Barclays	Boost Price Target
2/12/2021	Alnylam Pharmaceuticals	HC Wainwright	Boost Price Target
1/25/2021	Alnylam Pharmaceuticals	BMO Capital Markets	Downgrade
1/13/2021	Alnylam Pharmaceuticals	Cowen	Boost Price Target
12/17/2020	Alnylam Pharmaceuticals	Piper Sandler	Boost Price Target
11/24/2020	Alnylam Pharmaceuticals	SVB Leerink	Boost Price Target
10/15/2020	Alnylam Pharmaceuticals	Bank of America	Lower Price Target
10/12/2020	Alnylam Pharmaceuticals	Chardan Capital	Reiterated Rating
9/30/2020	Alnylam Pharmaceuticals	Oppenheimer	Reiterated Rating
9/30/2020	Alnylam Pharmaceuticals	Berenberg Bank	Initiated Coverage
11/9/2020	Royalty Pharma	UBS Group	Upgrade
7/14/2020	Royalty Pharma	Evercore ISI	Initiated Coverage
7/13/2020	Royalty Pharma	SunTrust Banks	Initiated Coverage
7/13/2020	Royalty Pharma	JPMorgan Chase & Co.	Initiated Coverage
7/12/2020	Royalty Pharma	The Goldman Sachs Group	Initiated Coverage
12/10/2020	CureVac	Credit Suisse Group	Downgrade
9/8/2020	CureVac	Jefferies Financial Group	Initiated Coverage
3/2/2021	Catalent	Argus	Boost Price Target
11/5/2020	Catalent	Deutsche Bank Aktiengesellschaft	Boost Price Target
11/4/2020	Catalent	Robert W. Baird	Boost Price Target

(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources